Kovack Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $574K | Buy |
741
+240
| +48% | +$184K | 0.03% | 551 |
|
|
2025
Q4 | $387K | Buy |
501
+118
| +31% | +$80.1K | 0.02% | 677 |
|
|
2025
Q3 | $216K | Buy |
+383
| New | +$217K | 0.02% | 546 |
|
|
2025
Q2 | – | Sell |
-333
| Closed | -$211K | – | 649 |
|
|
2025
Q1 | $211K | Buy |
333
+11
| +3% | +$7.57K | 0.02% | 523 |
|
|
2024
Q4 | $229K | Hold |
322
| – | – | 0.02% | 531 |
|
|
2024
Q3 | $338K | Sell |
322
-10
| -3% | -$11.1K | 0.04% | 413 |
|
|
2024
Q2 | $349K | Hold |
332
| – | – | 0.04% | 385 |
|
|
2024
Q1 | $320K | Hold |
332
| – | – | 0.04% | 330 |
|
|
2023
Q4 | $292K | Sell |
332
-3
| -0.9% | -$2.47K | 0.03% | 420 |
|
|
2023
Q3 | $276K | Buy |
335
+6
| +2% | +$4.71K | 0.04% | 416 |
|
|
2023
Q2 | $236K | Sell |
329
-51
| -13% | -$39.3K | 0.03% | 472 |
|
|
2023
Q1 | $312K | Buy |
380
+55
| +17% | +$41.5K | 0.04% | 403 |
|
|
2022
Q4 | $234K | Sell |
325
-10
| -3% | -$7.38K | 0.03% | 477 |
|
|
2022
Q3 | $231K | Sell |
335
-799
| -70% | -$503K | 0.03% | 480 |
|
|
2022
Q2 | $670K | Sell |
1,134
-521
| -31% | -$339K | 0.09% | 251 |
|
|
2022
Q1 | $1.16M | Buy |
1,655
+282
| +21% | +$178K | 0.12% | 179 |
|
|
2021
Q4 | $867K | Sell |
1,373
-108
| -7% | -$66.4K | 0.08% | 261 |
|
|
2021
Q3 | $896K | Buy |
1,481
+1,086
| +275% | +$674K | 0.1% | 237 |
|
|
2021
Q2 | $221K | Buy |
+395
| New | +$200K | 0.03% | 610 |
|
|
2020
Q3 | – | Sell |
-365
| Closed | -$228K | – | 556 |
|
|
2020
Q2 | $228K | Buy |
+365
| New | +$207K | 0.04% | 373 |
|
|
2019
Q2 | – | Sell |
-556
| Closed | -$228K | – | 506 |
|
|
2019
Q1 | $228K | Buy |
+556
| New | +$229K | 0.06% | 352 |
|
|
2018
Q4 | – | Sell |
-511
| Closed | -$206K | – | 480 |
|
|
2018
Q3 | $206K | Sell |
511
-230
| -31% | -$87.5K | 0.05% | 385 |
|
|
2018
Q2 | $256K | Sell |
741
-255
| -26% | -$79.8K | 0.07% | 314 |
|
|
2018
Q1 | $343K | Buy |
996
+199
| +25% | +$69.2K | 0.09% | 270 |
|
|
2017
Q4 | $300K | Sell |
797
-320
| -29% | -$130K | 0.08% | 306 |
|
|
2017
Q3 | $499K | Buy |
1,117
+20
| +2% | +$9.52K | 0.17% | 147 |
|
|
2017
Q2 | $539K | Sell |
1,097
-1,279
| -54% | -$560K | 0.17% | 150 |
|
|
2017
Q1 | $921K | Buy |
2,376
+1,424
| +150% | +$528K | 0.36% | 57 |
|
|
2016
Q4 | $349K | Buy |
+952
| New | +$362K | 0.17% | 148 |
|
Other funds holding REGN
VCM
N
Kovack Advisors's REGN Position: Q1 2026 in Review
Kovack Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 48% in Q1 2026, buying an estimated $184K and bringing the position to 741 shares worth $574K. The position accounts for 0.03% of the portfolio, ranked #551.
Kovack Advisors first reported a position in REGN in Q4 2016 and has held it in 29 quarters since. The position peaked at $1.16M in Q1 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Kovack Advisors held 741 shares of Regeneron Pharmaceuticals worth $574K as of Q1 2026.
- Kovack Advisors bought 240 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $184K.
- Regeneron Pharmaceuticals made up 0.03% of Kovack Advisors's portfolio in Q1 2026, its #551 holding.
- Kovack Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 29 quarters since.
- Kovack Advisors's Regeneron Pharmaceuticals position peaked at $1.16M in Q1 2022.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.